» Articles » PMID: 37290699

Associations of N-terminal Pro-B-type Natriuretic Peptide, Estimated Glomerular Filtration Rate, and Mortality in US Adults

Abstract

Background: NT-proBNP is an important predictor of mortality but is inversely related to estimated glomerular filtration rate (eGFR). Whether the prognostic value of NT-proBNP is similar at different levels of kidney function is unknown.

Aims: We evaluated the association of NT-proBNP with eGFR and its implications for all-cause and cardiovascular mortality risk in the general population.

Methods: We included adults without prior cardiovascular disease from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. We used linear regression to characterize the cross-sectional associations of NT-proBNP with eGFR. We used Cox regression to assess the prospective associations of NT-proBNP with mortality across categories of eGFR.

Results: Among 11,456 participants (mean age 43 years, 48% female, 71% White, 11% Black), there was an inverse association between NT-proBNP and eGFR, which was stronger in those with more impaired kidney function. Per 15-unit decrease in eGFR, NT-proBNP was 4.3-fold higher for eGFR<30; 1.7-fold higher for eGFR 30 to 60, 1.4-fold higher for eGFR 61 to 90, 1.1-fold higher for eGFR 91 to 120 mL/min/1.73 m. Over a median 17.6 years of follow-up, 2,275 deaths (622 cardiovascular) occurred. Higher NT-proBNP was associated with higher all-cause (HR per doubling of NT-proBNP: 1.20, 95% CI: 1.16-1.25) and cardiovascular mortality (HR: 1.34, 95% CI 1.25-1.44). Associations were similar across eGFR categories (P-interaction >.10). Adults with NT-proBNP≥450 pg/mL and eGFR<60 mL/min/1.73m had 3.4-fold higher all-cause mortality and 5.5-fold higher cardiovascular mortality risk, compared to those with NT-proBNP<125 pg/mL and eGFR>90 mL/min/1.73m.

Conclusion: Despite its strong inverse association with eGFR, NT-proBNP has robust associations with mortality across the full range of kidney function in the general US adult population.

Citing Articles

N-terminal pro-B-type natriuretic peptide, eGFR, and progression of kidney disease in chronic kidney disease patients without heart failure.

Lu Y, Chen J, Su L, Lukwaro A, Zhou S, Zheng S Clin Kidney J. 2024; 17(10):sfae298.

PMID: 39464259 PMC: 11503021. DOI: 10.1093/ckj/sfae298.


Physical Activity and Systemic Biomarkers in Persons With COPD: Insights from a Web-Based Pedometer-Mediated Intervention.

Berube M, Robinson S, Wan E, Mongiardo M, Finer E, Moy M Chronic Obstr Pulm Dis. 2024; 11(4):369-381.

PMID: 38809105 PMC: 11363971. DOI: 10.15326/jcopdf.2023.0472.

References
1.
Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll M . The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2009; 133(1):14-23. DOI: 10.1309/AJCP60HTPGIGFCNK. View

2.
Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

3.
Hickman P . Biomarkers and cardiac disease in patients with end-stage renal disease on dialysis. Clin Biochem Rev. 2011; 32(2):115-9. PMC: 3100278. View

4.
Potter L . Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011; 278(11):1808-17. PMC: 4495883. DOI: 10.1111/j.1742-4658.2011.08082.x. View

5.
Kim H, Januzzi Jr J . Natriuretic peptide testing in heart failure. Circulation. 2011; 123(18):2015-9. DOI: 10.1161/CIRCULATIONAHA.110.979500. View